Altimmune News

Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Terns Pharmaceuticals (TERN) and Altimmune (ALT)

TipRanksApr 3 08:11 ET

Altimmune Analyst Ratings

BenzingaApr 1 12:22 ET

Altimmune's Pemvidutide Shows Promise for Obesity Treatment, Justifying Buy Rating

TipRanksApr 1 12:15 ET

Altimmune Analyst Ratings

BenzingaMar 28 11:55 ET

Analysts Are Bullish on Top Healthcare Stocks: Moderna (MRNA), Altimmune (ALT)

TipRanksMar 28 08:00 ET

Analysts Offer Insights on Healthcare Companies: Altimmune (ALT), Kiora Pharmaceuticals (KPRX) and Actinium Pharmaceuticals (ATNM)

TipRanksMar 28 07:30 ET

Buy Rating Affirmed for Altimmune as Pemvidutide Shows Promising Weight Loss and Lean Mass Preservation

TipRanksMar 27 17:25 ET

Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Altimmune (ALT)

TipRanksMar 27 15:40 ET

Altimmune's Pemvidutide Poised for Market Success: A Buy Rating With a $25 Price Target

TipRanksFeb 26 14:45 ET

Analysts Conflicted on These Healthcare Names: Cogent Biosciences (COGT) and Altimmune (ALT)

TipRanksFeb 26 09:40 ET

Altimmune (ALT) Gets a Buy From Piper Sandler

TipRanksFeb 15 08:55 ET

Buy Rating for Altimmune Backed by Pemvidutide's Promise and Market Potential

TipRanksFeb 13 22:35 ET

Altimmune Analyst Ratings

BenzingaFeb 13 18:01 ET

Altimmune's Pemvidutide Shows Promising Outlook in NASH and Obesity Markets: A Strong Buy Rating

TipRanksFeb 6 15:15 ET

Altimmune Analyst Ratings

BenzingaJan 24 07:02 ET

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), 10x Genomics (TXG) and Altimmune (ALT)

TipRanksJan 22 14:10 ET

Analysts Conflicted on These Healthcare Names: Legend Biotech (LEGN), Altimmune (ALT) and Apellis Pharmaceuticals (APLS)

TipRanksJan 12 08:30 ET

Buy Rating for Altimmune's Pemvidutide: A Promising Candidate for NASH Resolution and Fibrosis Improvement

TipRanksJan 8 00:35 ET

Analysts Offer Insights on Healthcare Companies: Altimmune (ALT) and Atricure (ATRC)

TipRanksDec 4, 2023 07:40 ET

HC Wainwright & Co. Reiterates Buy on Altimmune, Maintains $15 Price Target

BenzingaDec 1, 2023 14:28 ET